Abstract
Leukotrienes have been recognized as mediators of inflammatory allergic diseases of the lung (22). Consequently, antileukotriene therapy appears to be nearly established as novel pharmacotherapy of allergic asthma (15, 31). Cysteinyl-leukotrienes (LTC4, LTD4, LTE4) appear to have considerable pathophysiological importance in allergie asthma, because functional lung parameters improve with antileukotriene therapy after LTD4 challenge, antigen provocation, cold air exposure, exercise-induced asthma, and even aspirin-induced asthma (22, 24, 46). Effective antileukotriene therapy comprises various LTD4 receptor antagonists (LTD4ra) and 5-lipoxygenase (5-LOX) inhibitors (15, 22). 5-LOX inhibitors can be differentiated into the direct 5-LOX inhibitors (LOI) and FLAP (Five Lipoxygenase Activating Protein) binding leukotriene synthesis inhibitors (LSI) (Figure 1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abramovitz M., Wong E., Cox E. M., Richardson C.D., Li C., and Vickers P.J., 1993, 5-lipoxygenase-ac-tivating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase, Eur. J. Biochem. 215: 101–111.
Barnes P.J., 1992, New aspects of asthma, J. Internal Med. 231: 453–461.
Bell, R.L., Young, R.R., Albert D., Lanni C., Summers J.B., Brooks D.W., Rubin P. and Carter G.W., 1992, The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor, Int. J. Immunopharmac. 14: 505–510.
Capriotti A.M., Furth E.E., Arrasmith M.E., and Laposata M., 1988, Arachidonate released upon agonist stimulation preferentially originates from arachidonate most recently incorporated into nuclar membrane phospholipids, J. Biol Chem. 263: 10029–10034.
Carter G.W., Young P.R., Albert D.H., Bouska J., Dyer R., Bell R.L., Summers J.B., Brooks D.W., 1991, 5-lipoxygenase inhibitory activity of zileuton, J. Pharmacol. Exp. Ther. 256: 929–937.
Chen X.-S., Sheller J.R., Johnson E.N. and Funk C.D., 1994, Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene, Nature 372: 179–182.
Courts S.M., Khandwala A., van Inwegen R., Chakraborty U., Musser J., Bruens J., Jariwala N., Dally-Meade V., Ingram R., Pruss T., Jones H., Neiss E., and Weinryb I., 1985, Arymethyl Phenyl Ethers. Anew class of specific inhibitors of 5-lipoxygenase. In: Bailey J.M. (ed.) Prostaglandins, Leukotrienes, and Lipoxins. Biochemistry, mechanism of action, and clinical applications. Plenum Press. New York and London, 627–637.
Dahlén S.E., Dahlén B., Ihre E., Kumiin M., Franzén L., Stensvad F., Larsson C., Blonqvist H., Björck T. and Zettelström O., 1993, The leukotriene biosynthesis inhibitor BAX X 1005 is a potent inhibitor of allergen-induced airway obstruction and leukotriene formation in man, Am. Rev. Resp. Dis. 147: A837.
Dixon R.A.F., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., Gillard J.W. and Miller D.K., 1990, Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis, Nature 343: 282–284.
Evans J.F., Leblanc Y., Fitzsimmons B.J., Charleson S., Nathaniel D. and Léveillé C., 1987, Activation of leukocyte movement and displacement of [3H] leukotriene B4 from leukocyte membrane preparations by (12R)-and (12S)-hydroxy-eicosatetraenoic acid, Biochim. Biophys. Acta 917: 406–410.
Evans J.F., Léveillé C., Mancini J.A., Prasit P., Thérien M., Zamboni R., Gauthier J.Y., Fortin R., Charleson Pl, Macintyre D.U., Luell S., Bach T.J. Meurer R. Guay J. Vickers P.J., Rouzer C.A., Gillard J.W., and Miller D.K., 1991, 5-lipoxyge-nase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors, Mol. Pharmacol. 40: 22–27.
Fischer A.R., Drazen J.M., Roth M., Rosenberg M.A., Loper M., Jungerwirth S., and Israel E., 1994, The effect of a leukotriene synthesis inhibitor, BAY X 1005 on bronchoconstriction induced by cold, dry air hyperventilation in asthmatics, Am. J. Resp. Crit. Care Med. 149: A1056.
Ford-Hutchinson A.W., 1993, 5-lipoxygenase activation in psoriasis: a dead issue?, Skin Pharmacol. 6: 292–297.
Fruchtmann R., Mohrs K.-H., Hatzelmann A., Raddatz S., Fugmann B., Junge B., Horstmann H. and Müller-Peddinghaus R., 1993, In vitro pharmacology of BAY X 1005, a new inhibitor of leukotriene synthesis, Agents Actions 38: 188–195.
Gardiner P.J., 1989, Inhibitors of the biosynthesis or actions of the leukotrienes, Asthma Rev. 2: 75–124.
Gardiner P.J., Cuthbert N.J., Francis H.P., Fitzgerald M.F., Thompson A.M., Carpenter T.G., Patel U.P., Newton B.B., Mohrs K., Müller-Peddinghaus R., Taylor W.A., 1994, Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY X 1005, Europ. J. Pharmacol. 258: 95–102.
Gorenne I., Labat C., Gascard J.P. Norel X., Müller-Peddinghaus R., Mohrs K.H., Taylor W.A., Gardiner P.J., and Brink C., 1993, (R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects of anti-IgE challenge in human airways, J. Pharmacol Exp. Therap. 268: 868–872.
Hatzelmann A., Fruchtmann R., Mohrs K.H. Raddatz S. and Müller-Peddinghaus R., 1993, Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 {(R)-2-[4-(quinolin-2-yl-methoxy) phenyl]-2-cyclopentyl acetic acid} and structurally related compounds, Biochem. Pharmacol. 45: 101–111.
Hatzelmann A., Goossens J., Fruchtmann R., Mohrs, K.H., Raddatz S., and Müller-Peddinghaus R., 1994, Inversely-correlated inhibition of human 5-lip-oxygenase activity by BAY X 1005 and other quinoline derivatives in intact cells and a cell-free system-implications for the function of 5-lipoxygenase activating protein, Biochem. Pharmacol. 47: 2259–2268.
Hatzelmann A., Fruchtmann R., Mohrs K.H., Raddatz S., Matzke M., Pleiss U., Keldenich J. and Müller-Peddinghaus R., 1994, Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase, Agents Actions 43: 64–68.
Hatzelmann A., Fruchtmann R., Mohrs K.-H., Raddatz S. and Müller-Peddinghaus R., 1994, Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4, Biochem. Pharmacol. 48: 32–39.
Henderson Jr. W.R., 1994, The role of leukotrienes in inflammation, Ann. Intern. Med. 121: 684–697.
Hill E., Maclouf J., Murphy R.C., and Henson P.M., 1992, Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity, J. Biol. Chem. 267: 22048–22053.
Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P. and Drazen J.M., 1990, The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air, New England J. Med. 323: 1740–1744.
de Jong E.M.G.J., van Vlijmen I.M.M.J., Schölte J.C.M. Buntinx A., Friedman B., Tanaka W., van de Kerkhof P.C.M., 1991, Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis, Skin Pharmacol. 4: 278–285.
Kargman S., Vickers P.J., and Evans J.F., 1992, A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells, J. Cell Biol. 119: 1701–1709.
Kast R., Fruchtmann R., Kupferschmidt R., Mohrs K.H., Raddatz S., Müller-Peddinghaus R., and Hatzelmann A., 1994, Role of 5-lipoxygenase-activating protein in the regulation of 5-lipoxygenase activity in human neutrophils, Agents Actions 41: C166–0168.
Kreisle R.A., Parker C.W., Griffin G.L., Senior R.M., and Stenson W.F., 1985, Studies of leukotriene B4-specific binding and function in rat polymorpho-nuclear leukocytes: absence of a chemotactic response, J. Immunology 134: 3356–3362.
Lagarde M., Gualde N. and Rigaud M., 1989, Metabolic interactions between eicosanoids in blood and vascular cells, Biochem J. 257: 313–320.
Lam B.K., Penrose J.F., Freeman G.J., and Austen K.F., 1994, Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4, Proc. Natl. Acad. Sci. USA 91: 7663–7667.
Larsen J.S. and Acosta E.P., 1993, Leukotriene-receptor anta-gonists and 5-lipoxygenase inhibitors in asthma, Ann. Pharmacother. 27: 898–903.
Laursen L.S., Naesdal. J. Bukhave K., Lauritsen K., Rask-Madsen J., 1990, Selective 5-lipoxygenase inhibition in ulcerative colitis, Lancet 335: 683–685.
Malaviya R., Malaviya R., and Jakschik B.A., Reversible trans-location of 5-lipoxygenase in mast cells upon IgE/antigen Stimulation, 1993, J. Biol Chem. 268: 4949–4944.
Mancini J.A., Abramovitz M., Cox M.E., Wong E., Charleson S., Perrier H., Wang Z., Prasit P. and Vickers P.J., 1993, 5-lipogygenase-activating protein is an arachidonate binding protein, FEBS Letters 318: 277–281.
Matzke M., Beckermann B., Fruchtmann R., Fugmann B., Gardiner P.J., Goossens J., Hatzelmann A., Junge B., Keldenich J., Kohlsdorfer C., Mohrs K.-H., Müller-Peddinghaus R., Raddatz S., 1994, Leukotriene synthesis inhibitors of the quinoline type: parameters for the optimization of efficacy, Proceedings XIIIth Interna-tional Symposium on Medicinal Chemistry, September 1994, Paris.
McColl S.R., Krump E., Naccache P.H., Caon A.C. and Borgeat P., 1989, Activation of the human neutrophil 5-lipoxygenase by exogenous arachidonic acid: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins, Br. J. Pharmacol. 97: 1265–1273.
McMillan R.M. and Walker E.R.H., 1992, Designing therapeutically effective 5-lipoxygenase inhibitors, TIPS 13: 323–330.
McMillan R.M., Spruce K.E., Crawley G.C., Walker E.R.H. and Foster S.J., 1992, Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase, Br. J. Pharmacol. 107: 1042–1047.
Meltzer S.S., Johns M.A., Rechsteiner E.A., Jungerwirth S., D’Amico J.M., Bleecker E.R., 1994, Bronchodilatory effects of BAY X 1005, a 5-lipoxygenase inhibitor in mild to moderate asthma, J. Allergy Clin. Immunol 93: 294, 792.
Miller D.K., Gillard J.W., Vickers P.J., Sadowski S., Léveillé C., Mancini J.A., Charleson P., Dixon R.A.E, Ford-Hutchinson A.W., Fortin R., Gauthier J.Y., Rodkey J., Rosen R., Rouzer C., Sigal I.S., Strader C.D. and Evans J.F., 1990, Identification and isolation of a membrane protein necessary for leukotriene production, Nature 343: 278.
Müller-Peddinghaus R., Fruchtmann R., Hatzelmann A., Kohlsdorfer C., Theisen-Popp P., and Horstmann H., 1991, Preclinical inflammatory pharmacology of leukotriene synthesis inhibitors. Hurdles and Perspectives. In: Hedqvist P., Kalden J.R., Müller-Peddinghaus R., Robinson D.W., eds. Trends ins RA-Research. Adv. Rheumatol Inflammation Vol. 1, Eular Publishers, Basel, 109–206.
Müller-Peddinghaus R., Malorny U., Kohlsdorfer C., Theisen-Popp P. and Sorg C., 1992, Acute inflammation in the mouse skin to study leukocyte infiltration and the influence of leukotriene synthesis inhibition. In: Müller-Peddinghaus R., ed. Leukotrienes and vascular phenomena of inflammation related to rheumatoid arthritis, Adv. Rheumatol. Inflammation Vol. 1, Eular Publishers, Basel, 73–82.
Müller-Peddinghaus R., Kohlsdorfer C., Theisen-Popp P., Fruchtmann R., Perzborn E., Beckermann B., Bühner K., Ahr H.-J. and Mohrs K.-H., 1993, BAY X 1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics, J. Pharmacol Exp. Ther. 267: 51–57.
Müller-Peddinghaus R., Kast R., Hatzelmann A., Gardiner P.J., 1993, Preclinical pharmacology of the FLAP (Five Lipoxygenase Activating Protein)-binding leukotriene synthesis inhibitor BAY X 1005. Proceedings of the Key West Workshop. Advances in understanding and treatment of asthma and COPD, December 1-2, 1993.
Musser J.H. and Kreft A., 1992, 5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors, J. Med. Chem. 35: 2501–2524.
Nasser S.M.S., Bell G.S., Hawksworth R.J., Spruce K.E., MacMillan R., Williams A.J., Lee T.H., Arm J.P., 1994, Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses, Thorax 49: 743–748.
Newsholme S.J., Griswold D.E. and Schwartz L., Conjunctival leukocyte infiltration evoked by leukotrienes: differing responses among rodent species, 1994, J. Lipid Mediators Cell Signalling 9: 197–203.
Percival M.D., 1991, Human 5-lipoxygenase contains an essential iron, J.Biol Chem. 266: 10058–10061.
Peters-Golden M. and McNish R.W., 1993, Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation, Biochem. Biophys. Res. Comm. 196: 147–153.
Powell W.S., 1984, Properties of leukotriene B4 20-hydroxylase from polymorphonuclear leukocytes, J. Biol Chem. 259: 3082–3089.
Powell W.S., Gravel S., MacLeod R.J., Mills E., and Hashefi M., 1993, Stimulation of human neutrophils by 5-oxo-6,8,11, 14-ei-cosatetraenoic acid by a mechanism independent of the leukotriene B4 receptor, J. Biol Chem. 268: 9280–9286.
Reid G.K., Kargman S., Vickers P.J., Mancini J.A., Léveillé C., Ethier D., Miller D.K., Gillard J.W., Dixon R.A.F., and Evans J.F., 1990, Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis, J. Biol. Chem. 265: 19818–19823.
Regier M.K., DeWitt D.L., Schindler M.S., and Smith W.L., 1993, Subcellular localization of prostaglandin endoperoxide synthase-2 in murine 3T3 cells, Arch. Biochem. Biophys. 301: 439–444.
Rouzer C.A. and Kargman S., 1988, Translocation of 5-lipoxy-genase to the membrane in human leukocytes challenged with ionophore A23187, J. Biol Chem. 263: 10980–10988.
Rouzer C.A., Ford-Hutchinson A.W., Morton H.E., and Gillard J.W., 1990, MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes, J. Biol Chem. 265: 1436–1442.
Samuelsson B. and Funk C.D., 1989, Enzymes involved in the biosynthesis of leukotriene B4, J. Biol Chem. 264: 19469–19472.
Schröder J.-M, 1989, The monocyte-derived neutrophil activating peptide (NAP/Interleukin 8) stimulates human neutrophil arachidonate-5-lipoxygenase, but not the release of cellular arachidonate, J. Exp. Med. 170: 847–863.
Steinhilber D., 1994, 5-lipoxygenase: enzyme expression and regulation of activity, Pharmac. Acta Helvetiae 69: 3–14.
Vanderhoek J.Y, Bryant R.W., and Bailey J.M., 1989, Inhibition of the leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid, J. Biol. Chem. 255: 10064–10066.
Weinblatt M.E., Kremer J.M., Coblyn J.S. Helfgott S., Maier A.L., Petrillo G., Henson B., Rubin P., and Sperling R., 1992, Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis, 1992, J. Rheumatol 19: 1537–1541.
Woods J.W., Evans J.F., Ethier D., Scott S., Vickers P.J., Hearn L., Heibein J.A., Charleson S., and Singer LL, 1993, 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes, J. Exp. Med. 178: 1935–1946.
Yamamoto S., 1992, Mammalian lipoxygenases: molecular structures and functions, Biochim. Biophys. Acta 1128: 117–131.
Young J.M., De Young L.M., 1989, Cutaneous models of inflammation for the evaluation of topical and systemic pharmacological agents, Modern Meth. Pharmacol. N.Y., 5: 215–231.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Müller-Peddinghaus, R., Kast, R. (1996). Leukotriene Synthesis (FLAP) Inhibition: Biochemistry and Pharmacology of Bay X 1005. In: Folco, G.C., Samuelsson, B., Maclouf, J., Velo, G.P. (eds) Eicosanoids. NATO ASI Series, vol 283. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0200-9_18
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0200-9_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0202-3
Online ISBN: 978-1-4899-0200-9
eBook Packages: Springer Book Archive